Charge control experiments on a CH-53E helicopter in a dusty environment

Charge control tests were carried out on a ground based, Marine Corps helicopter to determine if control of the electric fields acting on the engine exhaust gases could be used to reduce the electrification of the helicopter when it operated in a dusty atmosphere. The test aircraft was flown to a dusty, unpaved area and was then isolated electrically from the earth. When the helicopter engines were operated at ground idle with the rotor locked, the isolated aircraft charged positively, as had been observed previously. However, when the rotor brake was released and the turning rotor created a downdraft that raised dust clouds, the aircraft always became charged more positively, to potentials ranging form +30 to +45 kV. The dust clouds raised by the rotor downwash invariably carried negative space charges with concentrations of up to -100 nC/cu m and caused surface electric fields with strengths of up to 10 kV/m immediately down wind of the aircraft. The natural charging of the helicopter operating in these dust clouds was successfully opposed by control of the electric fields acting on the hot, electrically conductive exhaust gases. The control was achieved by placing electrostatic shield around the exhausts

Aircraft measurements of electrified clouds at Kennedy Space Center

The space-vehicle launch commit criteria for weather and atmospheric electrical conditions in us at Cape Canaveral Air Force Station and Kennedy Space Center (KSC) have been made restrictive because of the past difficulties that have arisen when space vehicles have triggered lightning discharge after their launch during cloudy weather. With the present ground-base instrumentation and our limited knowledge of cloud electrification process over this region of Florida, it has not been possible to provide a quantitative index of safe launching conditions. During the fall of 1988, a Schweizer 845 airplane equipped to measure electric field and other meteorological parameters flew over KSC in a program to study clouds defined in the existing launch restriction criteria. All aspects of this program are addressed including planning, method, and results. A case study on the November 4, 1988 flight is also presented

Aircraft measurements of electrified clouds at Kennedy Space Center, part 3

Flights made by the Special Purpose Test Vehicle for Atmospheric Research (SPTVAR) airplane during a second deployment to Florida during the summer of 1989 are discussed. The findings based on the data gathered are presented. The progress made during the second year of the project is discussed. The summer 1989 study was carried out with the support and guidance of Col. John Madura, Commander of Detachment 11, 2nd Weather Squadron, USAF, at Patrick Air Force Base (PAFB) and Cape Canaveral Air Force Station. The project goals were to develop and demonstrate techniques for measuring the electric field aloft and locating regions of charge during flight within and near clouds; to characterize the electric conditions that are presently identified as a threat to space launch vehicles; and to study the correlation between the electric field aloft and that at Kennedy Space Center's ground-based electric field mill array for a variety of electrified clouds

Compton Scattering Cross Section on the Proton at High Momentum Transfer

Cross-section values for Compton scattering on the proton were measured at 25 kinematic settings over the range s = 5-11 and -t = 2-7 GeV2 with statistical accuracy of a few percent. The scaling power for the s-dependence of the cross section at fixed center of mass angle was found to be 8.0 +/ 0.2, strongly inconsistent with the prediction of perturbative QCD. The observed cross-section values are in fair agreement with the calculations using the handbag mechanism, in which the external photons couple to a single quark.Comment: 5 pages, 5 figure

Angiotensin receptors in GtoPdb v.2023.1

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [63, 155]), which have around 30% sequence similarity. The decapeptide angiotensin I, the octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. losartan, candesartan, olmesartan, telmisartan, etc. are clinically used AT1 receptor blockers

Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [61, 152]), which have around 30% sequence similarity. The decapeptide angiotensin I, the octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. losartan, candesartan, telmisartan, etc. are clinically used AT1 receptor blockers

PharmacoSTORM nanoscale pharmacology reveals cariprazine binding on Islands of Calleja granule cells

Immunolabeling and autoradiography have traditionally been applied as the methods-of-choice to visualize and collect molecular information about physiological and pathological processes. Here, we introduce PharmacoSTORM super-resolution imaging that combines the complementary advantages of these approaches and enables cell-type- and compartment-specific nanoscale molecular measurements. We exploited rational chemical design for fluorophore-tagged high-affinity receptor ligands and an enzyme inhibitor; and demonstrated broad PharmacoSTORM applicability for three protein classes and for cariprazine, a clinically approved antipsychotic and antidepressant drug. Because the neurobiological substrate of cariprazine has remained elusive, we took advantage of PharmacoSTORM to provide in vivo evidence that cariprazine predominantly binds to D3 dopamine receptors on Islands of Calleja granule cell axons but avoids dopaminergic terminals. These findings show that PharmacoSTORM helps to quantify drug-target interaction sites at the nanoscale level in a cell-type- and subcellular context-dependent manner and within complex tissue preparations. Moreover, the results highlight the underappreciated neuropsychiatric significance of the Islands of Calleja in the ventral forebrain.NWO724.017.002Molecular Physiolog

Bocepreviralapú hármas kezelés hatékonyságának és biztonságosságának retrospektív elemzése előrehaladott fibrosisstádiumú, hepatitis C-vírus 1-es genotípussal fertőzött, korábban sikertelenül kezelt magyar betegeknél

INTRODUCTION: During 2011 and 2013, 155 Hungarian hepatitis C genotype 1 infected patients, mostly with advanced liver fibrosis, who did not respond to prior peginterferon + ribavirin dual therapy, started boceprevir based triple therapy in an early access program. AIM AND METHOD: Efficacy and safety of the therapy was retrospectively assessed based on sustained virologic responses, as well as on frequency and type of serious adverse events and of those leading to therapy discontinuation. RESULTS: In an intent-to-treat analysis 39.4% patients (61/155) reached sustained virologic response. Amongst pervious relapsers, partial responders and null-responders 59.5%, 41.4 % and 22.9% (p<0.05 compared to the other two categories) reached sustained virologic response, respectively, while amongst non-cirrhotics and cirrhotics 52.5% and 31.3% (p<0.05 compared to the non-cirrhotics) achieved sutained virologic response, respectively. Six out of the 33 most difficult to cure patients (previous null responder and cirrhotic) have reached sustained virologic response (18.2%). Frequency of early discontinuations due to insufficient virologic response was 31.1%, while due to adverse event 10.3%. Reported frequency of serious adverse event was 9.8%. These events represented anemia, diarrhoea, depression, agranulocytosis, elevated aminotransferases, generalized dermatitis and severe gingivitis with loss of teeth, prolonged QT interval on ECG, generalized oedema and severe dyspnoea, uroinfection, exacerbation of Crohn's disease, Campylobacter pylori infection and unacceptable weakness and fatigue. Eight patients received transfusion, 4 patients erythropoietin and 1 granulocyte colony stimulating factor during therapy. No death has been reported. CONCLUSIONS: With boceprevir based triple therapy, one of the bests available in 2011-2013 in Hungary, a relevant proportion of hepatitis C infected patients with advanced liver fibrosis achieved sustained viral response. In this cohort, side-effects resembled those reported in registration studies, and resulted in therapy discontinuation with consequent treatment failure in a relevant number of patients. Efficacy and tolerability of boceprevir-based triple therapy are suboptimal, particularly in the most difficult to cure patient population. Orv. Hetil., 2016, 157(34), 1366-1374